✦ LIBER ✦

The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics

✍ Scribed by C. Kazda; B. Gallwitz; R. Simó; J. R. Guzmán; P. Kraus; C. Nicolay; L. Rose; G. Schernthaner

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pathophysiological and Pharmacological R

✍ Grossman, Samuel S. 📂 Article 📅 2014 🏛 Springer Healthcare Communications 🌐 English ⚖ 442 KB

Long-term safety and efficacy of exenati

✍ Nobuya Inagaki; Kohjiro Ueki; Ayuko Yamamura; Hitoshi Saito; Takeshi Imaoka 📂 Article 📅 2011 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 295 KB

Exenatide once weekly for the treatment

✍ R. Pencek; A. Blickensderfer; Y. Li; S. C. Brunell; S. Chen 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 479 KB

Estimating the Long-Term Cost-Effectiven

✍ Michael E. Minshall; Alan K. Oglesby; Matthew E. Wintle; William J. Valentine; S 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 303 KB

Exenatide compared with long-acting insu

✍ M. J. Davies; R. Donnelly; A. H. Barnett; S. Jones; C. Nicolay; A. Kilcoyne 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 529 KB

Patient-reported outcomes in a trial of

✍ Kristina Secnik Boye; Louis S Matza; Alan Oglesby; Karen Malley; Sunny Kim; Risa 📂 Article 📅 2006 🏛 BioMed Central 🌐 English ⚖ 544 KB